Skip to content

MR-guided Tumour Boost

Prostate Cancer

This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.

null

Conditions de participation

  • Sexe:

    MALE

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Histologically-proven localized prostate cancer.
* Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
* Low-risk: cT1-T2a, PSA \<10, and Gleason score 6
* Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
* High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7
* Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume
* Planned for EBRT (+/- ADT)
* ECOG 0 or 1
* 18 years of age or older
* Ability to provide written informed consent to participate in the study

Exclusion Criteria:

* Prior radiotherapy to pelvis
* Radiological evidence of regional or distant metastases at the discretion of the treating physician.
* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
* Ataxia Telangectasia and SLE
* Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
* Severe claustrophobia

Lieu de l'étude

University Health Network, Princess Margaret Hospital
University Health Network, Princess Margaret Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Peter Chung, MB ChB

[email protected]
416 946 4501
Étude parrainée par
University Health Network, Toronto
Participants recherchés
Plus d'informations
ID de l'étude: NCT05364229